JPRN-UMIN000040434已完成未知
Verification of emission effects of hazardous substances by ingestion of test foods - Verification of emission effects of hazardous substances by ingestion of test foods
Square Clinic0 个研究点目标入组 5 人开始时间: 2020年12月25日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Those with serious diseases of the liver, kidney, heart, lung, digestive system, blood, endocrine system, and metabolic system 2) Those who have a disease requiring regular medication or a history of a serious disease requiring medication treatment 3) Those with a BMI of 26 or more 4) A person who regularly uses functional foods and supplements that may affect the discharge of hazardous substances 5) Those whose working hours are irregular due to night shift or irregular work 6) A person who smokes excessively or is a regular user of alcohol 7) Those whose lifestyle habits, such as eating and sleeping, are extremely irregular 8) Those who have donated blood within 4 weeks before obtaining consent 9) A person who has a history of hypersensitivity to test food ingredients 10) Those who are pregnant, lactating, or who intend to become pregnant during the examination period 11) Those who are participated in other clinical trials and monitored studies within one month prior to obtaining consent 12) Any other person deemed unsuitable as a subject by the study physician or study assignment physician
研究者
相似试验
尚未招募
Unknown
A clinical study to determine the safety and efficacy of an Oral Probiotic supplementation to improve Bacterial Vaginosis in females.CTRI/2024/05/067530Meteoric Biopharmaceuticals Pvt. Ltd.
尚未招募
Unknown
A clinical study to determine the safety and efficacy of an oral probiotic supplementation in reducing the risk of kidney stone in adults with recurrent kidney stone colic or acute episode of colicky pain.CTRI/2024/05/067236Meteoric Biopharmaceuticals Pvt. Ltd.
进行中（未招募）
1 期
A study to evaluate different dose levels of GlaxoSmithKline (GSK) Biologicals’ investigational Respiratory Syncytial Virus (RSV) vaccine (GSK3888550A), based on the safety of the vaccine and the antibodies (body defences) that the body produces following the vaccine administration, when given to healthy non-pregnant womeHealthy volunteers (Prevention of RSV LRTI in infants)MedDRA version: 20.1Level: LLTClassification code 10035692Term: Pneumonia due to respiratory syncytial virusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10038718Term: Respiratory syncytial virus bronchiolitisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10066741Term: Respiratory syncytial virus infection recurrentSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10052200Term: Respiratory syncytial virus infection NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10067384Term: Respiratory syncytial virus pneumonitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001340-62-FIGlaxoSmithKline Biologicals502
进行中（未招募）
1 期
A study to evaluate different dose levels of GlaxoSmithKline (GSK) Biologicals’ investigational Respiratory Syncytial Virus (RSV) vaccine (GSK3888550A), based on the safety of the vaccine and the antibodies (body defences) that the body produces following the vaccine administration, when given to healthy non-pregnant womeHealthy volunteers (Prevention of RSV LRTI in infants)MedDRA version: 20.1Level: LLTClassification code 10035692Term: Pneumonia due to respiratory syncytial virusSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10038718Term: Respiratory syncytial virus bronchiolitisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10066741Term: Respiratory syncytial virus infection recurrentSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10052200Term: Respiratory syncytial virus infection NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10067384Term: Respiratory syncytial virus pneumonitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001340-62-DEGlaxoSmithKline Biologicals500
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN®-Filo in Infants Aged 4-11 Months in Guinea and Sierra LeoneEbolaMedDRA version: 20.0Level: PTClassification code 10014071Term: Ebola diseaseSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-001331-10-Outside-EU/EEAJanssen Vaccines & Prevention B.V.